SCHEMBL3492383

SCHEMBL3492383

Fc1cccc(OCc2nnc(-c3ccc4c(c3)CCO4)o2)c1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 13/20 0.68
▸ POLB P06746 3/20 0.47
▸ TP53 P04637 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MAPT P10636 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ QPCT Q16769 1/20 0.43
▸ METAP2 P50579 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491254 0.81 GSK3B (1.00) GSK3BNPC1RAB9AMAPTKDM4E
SCHEMBL3492535 0.81 GSK3B (1.00) GSK3BNPC1RAB9AMAPTQPCT
SCHEMBL3493961 0.79 GSK3B (0.68) GSK3BPOLBTP53NPC1RAB9A
SCHEMBL3490598 0.79 GSK3B (0.68) GSK3BNPC1RAB9AMAPTMETAP2
SCHEMBL3494028 0.78 GSK3B (0.66) GSK3BNPC1RAB9AMAPTQPCT
SCHEMBL3492866 0.78 GSK3B (0.66) GSK3BNPC1RAB9AMAPTMETAP2
SCHEMBL3491930 0.75 GSK3B (0.61) GSK3BALDH1A1NPC1RAB9AMAPT
SCHEMBL3491210 0.73 GSK3B (1.00) GSK3BNPC1RAB9AMAPTQPCT
SCHEMBL3493208 0.73 GSK3B (1.00) GSK3B
SCHEMBL3491221 0.69 GSK3B (0.60) GSK3BTP53ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 — — US disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP GSK3B 1/4885POLB 2392/4885TP53 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback